Showing Results for: “diabetes”

Today, the American Diabetes Association® (ADA) and Blue Cross and Blue Shield of Minnesota announced a new endeavor to address disparities in maternal health care delivery, with an emphasis on the impact of gestational diabetes (GDM)—diabetes that occurs during pregnancy. A new professional education series will seek to eliminate provider biases and encourage implementation of the ADA’s Standards of Care in Diabetes (Standards of Care) to optimize maternal and infant health outcomes. GDM affects up to 9% of pregnancies in the U.S. and carries health risks for both mothers and children during

Tonight, President Biden urged in his State of the Union address that Congress take immediate action to finally address the prohibitive cost of insulin for people living with diabetes. The American Diabetes Association ® (ADA) joins this call on Congress to take swift action and pass legislation to cap monthly out-of-pocket insulin costs at $35 for Americans with commercial insurance, group health plans, and Medicare. The ADA has led the campaign resulting in the enactment of state-level out-of-pocket limits for insulin in 20 states and the District of Columbia. We've seen exactly how much

The American Diabetes Association® (ADA) applauds Alabama Governor Kay Ivey today for signing House Bill 249, legislation that will cap insulin co-sharing at $100 per month for those on state-regulated health plans, without regard to the policy deductible, and regardless of the quantity or type of insulin needed to fill the insured patient's prescription. Bill sponsor, Representative Paul Lee, Chairman of the House Health Committee and Senator Tom Butler, Chairman of the Senate Veteran’s and Military Affairs Committee provided leadership on this important legislation to reduce the burden of

The Rhode Island General Assembly’s Fiscal Year 2027 (FY 2027) budget adopted a policy change that limits Medicaid coverage of glucagon-like peptide-1 (GLP-1)-based medications to only individuals with type 2 diabetes. Beginning October 1, 2026, coverage for GLP-1-based medications prescribed for obesity or weight management will be eliminated. The American Diabetes Association ® (ADA) remains concerned that restricting evidence-based obesity treatment will result to poorer health and higher medical costs for individuals living with obesity in the state. Obesity costs Rhode Island’s economy an

Obesity is on the rise in the United States—for both adults and children. Today, it’s estimated that 40% of U.S. adults have obesity and nearly 90% of those living with diabetes have overweight or obesity. Obesity is a major contributor to disease and is linked to 200 medical conditions. In a recent American Diabetes Association ® (ADA) survey on the impact of health care costs, nearly 70% of respondents reported the high cost of health care being a primary barrier to health and 76% of respondents supported adding coverage for weight loss medications. “The ADA was pleased by the White House’s

The American Diabetes Association (ADA) and Novo Nordisk, one of the world's leading companies in diabetes management and long-time supporter of the ADA, announce the transition of their 15-year signature 5K@ADA Run/Walk event to a virtual challenge. The 5K@ADA has been an official event during the Scientific Sessions for 15 years and has brought together over 13,400 participants. Through the continued support of Novo Nordisk, the 5K@ADA Virtual Challenge is free of charge to all participants. Everyone is encouraged to sign up, lace up and head out the door, right from their home over the

Committee action marks a critical milestone toward making insulin more affordable for millions of Americans Today, the American Diabetes Association® (ADA) celebrated an important victory for people living with diabetes as critical provisions of the bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act advanced through the Senate Committee on Health, Education, Labor, and Pensions, bringing the legislation one step closer to becoming law. The committee’s action represents significant momentum in the effort to ensure individuals who get insulin through their

Results of the PIONEER 6 trial indicate oral semaglutide is safe for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk, according to results announced at the symposium titled “Oral Semaglutide—The PIONEER Program Trials” today at the American Diabetes Association’s® (ADA) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Oral semaglutide reduced cardiovascular death and all-cause mortality by nearly 50 percent, based on median follow up of 15.9 months. PIONEER 6 was conducted across 21 countries and included 3,183 participants who were randomized

New legislation in Illinois to make insulin more affordable for all Illinoisans who need it Today, Illinois Governor J.B. Pritzker signed legislation that will cap insulin co-pays. Senate Bill 667 (SB 667) also requires the Illinois Department of Insurance to issue a report that includes a summary of insulin pricing practices as well as public policy recommendations to control and prevent overpricing of prescription insulin drugs made available to Illinois consumers. The American Diabetes Association (ADA) applauds Governor Pritzker and bill sponsors Senator Andy Manar and Representative Will

In an analysis of the AWARD-7 study, people with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease (CKD) who took 1.5 mg of dulaglutide once weekly had a reduction of clinical events associated with end-stage kidney disease (ESKD) including dialysis and with a kidney transplant, and a slower rate of kidney function decline compared to people who used insulin or a lower dose of dulaglutide. The study is an abstract titled “Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) Versus Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria